Concepedia

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Hidetoshi Hayashi, Junji Tsurutani, Taro Satoh, Norikazu Masuda, Wataru Okamoto, Ryotaro Morinaga, Masaaki Terashima, Masaki Miyazaki, Isamu Okamoto, Yukihiro Nishida,

Breast Cancer · 2011 · 16 citations · 16 references

DOI

Concepts

References

16

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

, , +10

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

D Ennis J. S Lamon, B Rian L Eyland, Sarah Hak et al. · 2009 · 1.2K citations

, , +10

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortés, Joyce O’Shaughnessy, David Loesch et al. · The Lancet · 2011 · 1.1K citations

, , +9

Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan

Federico Innocenti, Samir D. Undevia, Lalitha Iyer et al. · Journal of Clinical Oncology · 2004 · 954 citations · Full text

, , +17

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar et al. · Journal of Clinical Oncology · 1999 · 791 citations

, , +16